Direct Biologics Introduces AmnioWrap™: A Groundbreaking Advancement in Regenerative Medicine
New Placental Allograft Enhances Product Line Alongside Market-Leading ExoFlo™ Extracellular Vesicles
AUSTIN, Texas (FreePR.org) -- Direct Biologics, LLC, a pioneer in extracellular vesicle technology, has announced the launch of AmnioWrap™, a cutting-edge placental-based sheet allograft now available for clinical use. Designed for applications in acute and chronic wounds, AmnioWrap™ is a tri-layer graft that incorporates a collagen extracellular matrix alongside an array of regulatory proteins, including growth factors, cytokines, and chemokines—key components known to promote healing and tissue regeneration.
Joe Schmidt, Co-Founder and President of Direct Biologics, emphasized the significance of this new addition: “Our team’s extensive expertise in commercial, scientific, and clinical applications of amniotic allografts has culminated in the development of AmnioWrap™. With this innovation, we are expanding our regenerative therapeutic platform and providing transformative solutions for patients in 2021.”
Adam McQueen, Division Vice President of Amniotic Products, expressed enthusiasm about the product’s potential: “Amniotic tissue is one of the most comprehensive regenerative tools, supported by substantial clinical and scientific research. AmnioWrap™ is poised to make a significant impact across multiple surgical applications.”
AmnioWrap™ is available in a range of sizes, making it suitable for use in plastic and reconstructive surgery, orthopedic and spinal procedures, surgical wounds, and treatment of burns, chronic wounds, and ocular injuries.
Mark Adams, Co-Founder and CEO, commented, “The introduction of AmnioWrap™ exemplifies our commitment to meeting the needs of clinicians across diverse therapeutic disciplines. Placental allografts are an essential and rapidly growing segment of the regenerative medicine market.”
Chief Medical Officer Vik Sengupta, MD, added, “AmnioWrap™ empowers clinicians with an additional tool to address unique patient needs, aiding in wound healing, limb salvage, and reducing surgical complications, ultimately enhancing patient quality of life.”
In addition to launching AmnioWrap™, Direct Biologics is actively enrolling participants in its national, multi-center Phase II clinical trial (EXIT COVID-19), which evaluates the use of ExoFlo™ for treating COVID-19-related acute respiratory distress syndrome (ARDS).
About AmnioWrap™
AmnioWrap™ is a sterilized, dehydrated human amniotic/chorionic membrane allograft designed for homologous use in tissue repair, reconstruction, and augmentation. The product features an intact extracellular matrix (ECM), growth factors, and cytokines derived from human placental tissues. Its versatile design and ease of application make it ideal for surgical wounds, burns, soft tissue injuries, and various other applications.
About ExoFlo™
ExoFlo™ is an investigational extracellular vesicle product derived from human bone marrow mesenchymal stem cells (MSCs). Though not yet FDA-approved, ExoFlo™ has demonstrated the ability to modulate inflammation and facilitate intercellular communication, providing promising therapeutic potential.
About Direct Biologics
Headquartered in Austin, Texas, with a state-of-the-art R&D facility at the University of California and an operations center in St. Louis, Missouri, Direct Biologics is a leader in regenerative medicine innovation. The company specializes in developing and manufacturing advanced biologic products, including its flagship extracellular vesicle-based therapies. Committed to advancing the science of regenerative healing, Direct Biologics is pursuing FDA approval for additional clinical applications of its cutting-edge technologies.
For more information, visit www.directbiologics.com.
Contact Information
Phone: 1-800-791-1021
Email: info@directbiologics.com
###
Sponsor Message
Medications like Lipitor, Crestor, and Nexium are available at lower costs from Canadian pharmacies, helping millions of Americans save. For those with diabetes, insulin options like Humalog and Lantus are essential, while patients with asthma and COPD benefit from Advair Diskus and Ventolin inhalers. Trusted drugs like Zoloft, Prozac, and Abilify are vital for mental health, while Eliquis, Plavix, and Xarelto help protect cardiovascular health. Commonly purchased medications include Celebrex for managing pain and Synthroid for thyroid replacement therapy. Additionally, erectile dysfunction can be treated with medications like Viagra and Cialis, and Type 2 diabetes is managed with Januvia. Provigil and Nuvigil are trusted wakefulness aids for those dealing with narcolepsy or extreme daytime sleepiness. Affordable options like Cymbalta for nerve pain and Aricept for Alzheimer's are made available to American patients through Canadian pharmacies.
